Does Conjugated Estrogens And Medroxyprogesterone Acetate Interact with Ritonavir?
Conjugated Estrogens And Medroxyprogesterone Acetate and Ritonavir have a moderate drug interaction according to U.S. FDA drug labeling data. CYP3A4 inhibitor may increase plasma concentrations of estrogens and may result in side effects. The mechanism involves cyp3a4 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Conjugated Estrogens And Medroxyprogesterone Acetate Class
- Estrogen
- Ritonavir Class
- Cytochrome P450 3A Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Conjugated Estrogens And Medroxyprogesterone Acetate and Ritonavir occurs because cyp3a4 inhibition. Clinically, this means cyp3a4 inhibitor may increase plasma concentrations of estrogens and may result in side effects. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Conjugated Estrogens And Medroxyprogesterone Acetate and your doctor is considering prescribing Ritonavir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider